ABSTRACT. In order to evaluate the usefulness of liposomes, which are stable in acidic solution, bile and pancreatin solution (stable liposomes), as vehicle for oral vaccines, the intestinal IgA antibody responses of mice to liposome-associated antigen after oral administration were examined. The intestinal IgA antibody responses against ganglioside GM1 were detected after the oral immunization of ganglioside GM1-containing stable liposomes. When monophosphoryl lipid A was incorporated into stable liposomes containing ganglioside GM1, further augmentation of IgA responses to ganglioside GM1 was observed. On the other hand, the oral administration with ganglioside GM1 alone was unable to induce any detectable intestinal anti-ganglioside GM1 IgA antibody response. These results suggest that liposomes which are stable in acidic solution, bile, and pancreatin solution would serve effectively as an oral delivery vehicle for inducing mucosal immune responses. -KEY WORDS: liposome, mucosal immunity, oral vaccine.
solution [13] , suggesting that these stable liposomes have potential for developing oral vaccines. So far, several studies have reported on in vitro and in vivo stability of liposomes in gastric and intestinal fluid [3, 4, 13, 26] . However, the potential of stable liposomes as a delivery system to stimulate intestinal IgA antibody response has never been explored. Therefore, it is important to examine the effectiveness of oral immunization with stable liposomes in eliciting intestinal IgA antibody response for their practical application of oral vaccine.
In the present study, in order to reveal the potential of stable liposomes as oral vaccine, we examined S-IgA antibody response to antigen associated with stable liposomes.
DPPS, Chol, monophosphoryl lipid A (MPL), trypsin inhibitor (soybean type I-S) (Sigma Chemical Co., St. Louis, Mo), DPPC (Nippon Fine Chemical, Osaka), and DSPC (Nippon Oil & Fats, Tokyo) were commercial products. Ganglioside GM1 and pancreatin were purchased from Wako Pure Chemical Industries, Osaka. BALB/c mice were purchased from Charles River Japan, Tokyo.
Liposomes for oral administration were prepared from lipid mixture solution containing DPPC, DPPS and Chol in a molar ratio of 1:1:2 (total amount, 2 µmol), DSPC and Chol in a molar ratio of 7:2 (total amount, 2.03 µmol), and DSPC, DPPS, and Chol in a molar ratio of 7:3:2 or 1:1:2 (total amount, 2 µmol), respectively, as described previously [13] . All the liposomes were supplemented with ganglioside GM1 (0.05 µmol) as a model antigen.
Four-week-old female BALB/c mice were orally immunized in groups of 5 as follows: group A, liposomes composed of DPPC (0.5 µmol), DPPS (0.5 µmol), Chol (1.0 µmol), and ganglioside GM1 (0.05 µmol); group B, liposomes composed of DSPC (1.58 µmol ), Chol (0.45 µmol ), and ganglioside GM1 (0.05 µmol); group C, liposomes composed of DSPC (1.17 µmol), DPPS (0.5
Oral administration of antigens induces the appearance of secretory immunoglobulin A (S-IgA) antibodies which play an important role as a first line of defense against microorganisms that infect via mucosal surfaces [14, [16] [17] [18] [19] 22 ] not only at the site of antigen application (gut) but also in other external secretions, due to the dissemination of antigen-sensitized cells to other tissues [14, [16] [17] [18] [19] 22] . Therefore, the oral route of immunization is a trustworthy way to induce a mucosal S-IgA antibody responses. However, this immunization route has the problem of antigen degradation by gastric acidity and proteolytic enzymes in the intestinal lumen, and extremely large doses are required to achieve adequate immune response.
Liposomes, which are bilayer vesicles composed of amphiphilic phospholipids, have been used as delivery systems for a wide variety of biologically active substance to specific tissues, and have also been used as adjuvants to enhance the immune response to several bacterial and viral antigens [9, 11, 20] . In particular, since the liposomesentrapped materials are protected from enzymatic attack until they reach the target sites, the potential usefulness of liposomes as carriers and adjuvants for developing oral vaccines has attracted considerable interest during the last few years [1] . Thus far, the oral administration of liposomes has been undertaken for antigens of parasite [25] and bacteria [5, 7, 8, 10, 12, 21, 24, 29] . Their potential as adjuvants has been demonstrated in several studies [21, 25] . However, the critical point in the oral use of liposomes is the stability of the vesicles in the harsh environment of the gastrointestinal tract. More recently, we have demonstrated that liposomes composed of dipalmitoylphosphatidylcholine (DPPC), dipalmitoylphosphatidylserine (DPPS), and c h o l e s t e r o l ( C h o l ) ( 1 : 1 : 2 , m o l a r r a t i o ) , distearoylphosphatidylcholine (DSPC) and Chol (7:2, molar ratio), and DSPC, DPPS, and Chol (7:3:2 or 1:1:2, molar ratio) were stable in acidic solution, bile, and pancreatin µmol), Chol (0.33 µmol), and ganglioside GM1 (0.05 µmol); group D, liposomes composed of DSPC (0.5 µmol), DPPS (0.5 µmol), Chol (1 µmol), and ganglioside GM1 (0.05 µmol); group E, ganglioside GM1 alone (0.05 µmol). Other groups of 5 BALB/c mice were also orally immunized with liposomes composed of DPPC (0.5 µmol), DPPS (0.5 µmol), Chol (1.0 µmol), MPL (2 or 4 µg), and ganglioside GM1 (0.05 µmol) in a volume of 0.15 ml per mouse. Fourteen days after immunization, the mice were killed and the small intestine (30 cm from pylorus) was collected. The intestine from each mouse was cut into 1 cm pieces and transferred to a glass tube. After addition of 1 ml of PBS containing trypsin inhibitor (0.1 mg/ml), the tubes were vortexed gently for 30 sec, and centrifuged at 12,000 × g for 20 min. The supernatants were collected and assayed for antibody activity.
For determining specific antibody against ganglioside GM1, the enzyme-linked immunosorbent assay (ELISA) was performed as described previously [13] . Student's t-test was performed for statistical evaluation of the results. Less than 0.05 of p value was taken as the level of significance. Results are expressed as the arithmetic mean with the standard deviation of the mean (mean ± S.D.).
At first, stable liposomes containing ganglioside GM1 were administered orally to mice, and the intestinal IgA antibody responses to ganglioside GM1 were evaluated at 14 days after immunization. Table 1 shows the S-IgA antibody responses to antigen associated with stable liposomes after oral immunization. Production of anti-ganglioside GM1 IgA antibody was demonstrated in intestinal fluid from mice receiving liposomes composed of DPPC (0.5 µmol), DPPS (0.5 µmol), Chol (1.0 µmol), and ganglioside GM1 (0.05 µmol) (group A), DSPC (1.58 µmol ), Chol (0.45 µmol ), and ganglioside GM1 (0.05 µmol) (group B), DSPC (1.17 µmol), DPPS (0.5 µmol), Chol (0.33 µmol), and ganglioside GM1 (0.05 µmol) (group C), and DSPC (0.5 µmol), DPPS (0.5 µmol), Chol (1 µmol), and ganglioside GM1 (0.05 µmol) (group D), whereas no intestinal anti-ganglioside GM1 IgA antibody responses could be detected in mice immunized with 0.05 µmol of ganglioside GM1 alone (group E). The intestinal IgA level was significantly elevated in groups A (p<0.0005), B (p<0.02), C (p<0.001), and D (p<0.0001) compared with that in group E. Among groups A to D, the S-IgA antibody response against ganglioside GM1 was significantly higher in groups A (p<0.004), C (p<0.03), and D (p<0.0003) than in group B. The intestinal IgG and IgM activities against ganglioside GM1 were not detected in any mice in groups A to E.
Next, we evaluated the adjuvant MPL for its ability to potentiate the S-IgA immune response to liposomal antigen given by the oral route. One of the stable liposomes, i.e., liposomes made of DPPC, DPPS, and Chol in a molar ratio of 1:1:2, was supplemented with ganglioside GM1 (0.05 µmol) and MPL (2 or 4 µg) and used for oral immunization. Antibody response to liposomal antigen was evaluated at 14 days after the immunization.
As shown in Table 2 , mice given liposomes containing ganglioside GM1 and MPL exhibited significant higher intestinal IgA antibody responses than animals given liposomes containing ganglioside GM1 alone (without MPL) (p<0.02). The maximum augmentation of S-IgA antibody responses was obtained when a dose of 2 µg of MPL was given orally with the antigen. Higher dose of MPL (4 µg per mouse) did not potentiate the S-IgA response to the a) Three groups of 5 BALB/c mice were orally immunized with liposomes composed of DPPC (0.5 µmol), DPPS (0.5 µmol), Chol (1.0 µmol), MPL (0, 2, or 4 µg), and ganglioside GM1 (0.05 µmol) in a volume of 0.15 ml per mouse. Small intestinal wash samples were collected at 14 days after immunization and assayed for anti-ganglioside GM1 IgA, IgG, and IgM antibody by ELISA. b) Antibody activity was detected against ganglioside GM1 by ELISA with absorbance at 492 nm using a 1/60 dilution of small intestinal wash sample. c) p<0.02 compared with value for mice given liposomes containing ganglioside GM1 alone (without MPL). antigen to a greater degree than a dose of 2 µg of the adjuvant. On the other hand, production of both major immunoglobulin isotypes, i.e., IgG and IgM, were not enhanced by the oral administration of liposomes containing ganglioside GM1 and MPL. It has been shown that liposomes were taken up by M cells of rat Peyer's patches which have endocytic activity following intraluminal administration [6, 27] . Thus, liposomes which are stable in the gastrointestinal tract would be preferentially taken up by M cells through endocytosis when orally administered. In this study, the oral administration of ganglioside GM1-containing stable liposomes induced the intestinal IgA antibody responses directed against ganglioside GM1 (Table 1 , groups A to D). On the other hand, the oral administration of ganglioside GM1 alone was ineffective for the induction of the intestinal IgA antibody response against ganglioside GM1 (Table 1 , group E). These results suggest that stable liposomes are able to deliver to Peyer's patches without leakage or degradation of incorporated antigens during passage through the gastrointestinal tract and then to induce the intestinal IgA responses against antigen incorporated into liposomes. Furthermore, the poor immunogenicity of ganglioside antigen such as ganglioside GM1 is well documented [15] . Oral immunization of stable liposomes containing ganglioside GM1 in mice produced an intestinal IgA antibody response to ganglioside GM1, whereas that of ganglioside GM1 alone was unable to induce any detectable intestinal IgA response ( Table 1 ), indicating that stable liposomes possess innate adjuvant properties. Actually, the effectiveness of orally administered liposomes as adjuvants for mucosal immune responses has been demonstrated in several studies [7, 9, 20] .
Previously, it has been reported that liposomes containing phosphatidylserine (PS) were taken up depending on the PS concentration by rat Peyer's patches following intraluminal administration [27] . In the present study, the S-IgA antibody responses against ganglioside GM1 in mice immunized with stable liposomes lacking PS as a lipid component (group B) were significantly lower than those in mice immunized with stable liposomes containing PS [group A (p<0.004), group C (p<0.03), and group D (p<0.0003)] (Table 1 ). These findings indicate that stable liposomes containing PS would be an effective carrier to Peyer's patches.
Incorporation of immunostimulants into liposomes is also useful for the enhancement of the potency of liposomal vaccines. It has been established that MPL has the applicability as an adjuvant for use in human vaccines [28] . In addition, it has also been found that liposomes can serve as a vehicle that allows expression of the adjuvant activity of MPL [1, 2] . We, therefore, proposed MPL as an ideal immunopotentiating agent for liposomal vaccine. In this study, liposomes containing ganglioside GM1 and MPL induced S-IgA antibody responses in mice greater than those induced by liposomes containing ganglioside GM1 alone (Table 2 ). This suggests that MPL acts as effective adjuvant for potentiating IgA antibody responses on the intestinal mucosa when administered by oral route and that the adjuvant properties of liposomes can be further enhanced by inclusion of adjuvant such as MPL in liposomes. Furthermore, an intestinal IgA response directed against ganglioside GM1 was induced after oral administration of ganglioside GM1-containing stable liposomes, but neither the intestinal IgG nor the IgM antibody response against ganglioside GM1 was detected (Tables 1 and 2 ). Previously, it was shown that S-IgA response is peculiar to antigen when administered by oral route [19, 21] , which would explain the above observation.
Taking the findings obtained here into consideration, PShaving liposomes which are stable in acidic solution, bile and pancreatin solution, such as liposomes composed of DPPC, DPPS, and Chol (1:1:2, molar ratio) and DSPC, DPPS, and Chol (7:3:2 or 1:1:2, molar ratio), when administered by the oral route, would be useful for the effective carriers of antigens that are susceptible to degradation in the gastrointestinal environment to Peyer's patches. Furthermore, ganglioside GM1 was virtually nonimmunogenic by itself but was highly immunogenic in stable liposomes and was even more immunogenic in stable liposomes containing MPL (Tables 1 and 2 ). Thus, they would have potential in developing oral vaccines for antigens exhibiting poor immunogenicity.
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